The Atomo (ASX:AT1) share price is soaring today. Here's why

The Atomo (ASX: AT1) share price is up 4.8% today on news the company will be expanding access to its HIV self-test.

The Atomo Diagnostics Ltd (ASX: AT1) share price is up today after news the company's Mylan HIV self-test will be expanded in low and middle-income countries. At the time of writing, Atomo shares are trading for 22 cents apiece, 4.88% higher than yesterday's closing price. 

Let's take a closer look at the news driving the Atomo share price today.

A fit man flexes his muscles, indicating a positive share price movement on the ASX market

Image source: Getty Images

A step towards health equality

Atomo announced today that its distributer Viatris Inc has made an agreement with global health agency, Unitaid.

The multi-year partnership will see the cost of the Mylan HIV self-test lowered by 50%. Unitaid announced the test will become available for less than US$2 in 135 eligible countries.

The agency said the agreement was a key factor in meeting the global goal of having 90% of people aware of their HIV status. Currently, an estimated 8 million people do not know their HIV status.

Atomo designs and manufactures the HIV self-test. Unlike standard, multi-component HIV tests, it's a handheld device that Atomo says offers "unmatched usability". It works to detect the presence of HIV antibodies in a fingertip blood sample.

The test is prequalified by the World Health Organisation (WHO). WHO has estimated the global HIV self-testing market will increase by around 163% in coming years, demanding 29 million tests by 2025.

Commentary from management

Atomo's co-founder and managing director John Kelly said the partnership signaled a step-up in demand for the HIV self-tests: 

This agreement is not just a significant and important moment in the growth of Atomo, it's also further confirmation of the versatility and performance of our unique all-in-one diagnostic test platforms and drives lower costs across the business.

Not only have they proven themselves to be ideal for novel test applications like COVID-19 and anti-microbial resistance, but they are also suitable for deployment as part of mass-screening programs in decentralised settings.

Atomo share price snapshot

The Atomo share price needs all the good news it can get today – it's had a poor run on the ASX lately.

Currently, the Atomo share price is down 30% year to date and has fallen 55% over the last 12 months.

The company has a market capitalisation of around $83 million, with approximately 568 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can CSL continue delivering very healthy returns?

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Telix shares just crashed 12% on merger news. Time to buy the dip?

Integration, regulatory milestones and dilution are the real tests now.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Sigma Healthcare vs Sonic Healthcare: Which ASX healthcare share wins?

I compare Sigma Healthcare and Sonic Healthcare to reveal which ASX healthcare share I think is the better buy right…

Read more »

A man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Opinions

CSL shares are back near $180. Here's the level I'm watching

CSL shares are nearing a key technical level after a strong rebound.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best?

How do Neuren Pharmaceuticals and Telix Pharmaceuticals stack up? Here’s my verdict on which ASX healthcare stock looks more compelling…

Read more »